Global News Aggregator
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after…
Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial…
There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week…
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated…
Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000…
Evercore ISI’s Julian Emanuel thinks Nvidia’s monster rally is fueling a fear of missing out in the market. He finds clients, including many who traded through the dot-com boom and…
Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more…
A new study adds to evidence that severe obesity is becoming more common in young US children. There was some hope that children in a government food program might be…
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long…
Two experts see major challenges facing the adoption of new obesity drugs. Dr. Kavita Patel, a physician and NBC News medical contributor, believes fresh data from Novo Nordisk on Ozempic’s…